Appili Therapeutics Inc.
APLI.TOTSXHealthcare● Active
$0.02
+$0.00(+0.00%)
Market Cap$1925490
P/E Ratio—
52W High$0.04
52W Low$0.01
Appili Therapeutics Inc. (APLI.TO) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
APLI.TO · earnings · updated Jun 9, 2026
Latest Earnings
Q1 FY2026Report Date: Feb 12, 2026EPS Actual
-$0.01
Revenue
$0.00B
Fiscal Period
Q1 FY2026
FY ends December
Report Date
Feb 12, 2026
After Market Close
✓ 1-Quarter EPS Beat Streak
APLI.TO reports quarterly as a TSX-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.20
Rev. $3.00B
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.20
Rev. Est.$3.00B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Jul 1, 2026 | -$0.05 | — | — | — | $0.00B | — |
| — Q1 FY2026 | Feb 12, 2026 | — | -$0.01 | — | $0.00B | — | — |
| — Q4 FY2025 | Nov 20, 2025 | — | -$0.01 | — | $0.00B | — | — |
| — Q3 FY2025 | Aug 19, 2025 | — | -$0.01 | — | — | — | — |
| — Q1 FY2025 | Feb 11, 2025 | — | -$0.00 | — | $0.00B | — | — |
| — Q4 FY2024 | Nov 14, 2024 | — | -$0.01 | — | $0.00B | — | — |
| — Q3 FY2024 | Aug 13, 2024 | — | -$0.01 | — | — | — | — |
| ▲ Q2 FY2024 | Jun 25, 2024 | -$0.01 | $0.00 | +119.0% | $-0.00B | — | — |
Q3 FY2026
Jul 1, 2026
EPS Actual
—
EPS Est.
-$0.05
EPS Surpr.
—
Revenue
—
Q1 FY2026
Feb 12, 2026
EPS Actual
-$0.01
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q4 FY2025
Nov 20, 2025
EPS Actual
-$0.01
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q3 FY2025
Aug 19, 2025
EPS Actual
-$0.01
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q1 FY2025
Feb 11, 2025
EPS Actual
-$0.00
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q4 FY2024
Nov 14, 2024
EPS Actual
-$0.01
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q3 FY2024
Aug 13, 2024
EPS Actual
-$0.01
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q2 FY2024
Jun 25, 2024Beat
EPS Actual
$0.00
EPS Est.
-$0.01
EPS Surpr.
+119.0%
Revenue
$-0.00B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q1 FY2029 | $-0.01 | $-0.01 | $-0.01 | 1 |
| Q4 FY2028 | $-0.01 | $-0.01 | $-0.01 | 1 |
| Q3 FY2028 | $-0.02 | $-0.02 | $-0.02 | 1 |
| Q2 FY2028 | $-0.03 | $-0.03 | $-0.03 | 1 |
| Q1 FY2028 | $-0.02 | $-0.02 | $-0.02 | 1 |
| Q4 FY2027 | $-0.03 | $-0.03 | $-0.03 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q1 FY2029 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| — Q1 FY2026 | Feb 12, 2026 | — | $0.03 | $0.02 | -20.00% |
| — Q4 FY2025 | Nov 20, 2025 | — | $0.02 | $0.03 | +25.00% |
| — Q3 FY2025 | Aug 19, 2025 | — | $0.02 | $0.02 | +0.00% |
| — Q1 FY2025 | Feb 11, 2025 | — | $0.04 | $0.04 | +0.00% |
| — Q4 FY2024 | Nov 14, 2024 | — | $0.04 | $0.03 | -14.29% |
| — Q3 FY2024 | Aug 13, 2024 | — | $0.04 | $0.04 | +14.29% |
| ▲ Q2 FY2024 | Jun 25, 2024 | +119.0% | $0.05 | $0.04 | -11.11% |
| ▼ Q1 FY2024 | Feb 13, 2024 | -100.0% | $0.03 | $0.03 | +0.00% |
Q1 FY2026-20.00%
Report Date
Feb 12, 2026
EPS Beat/Miss
—
Price Before
$0.03
Price After
$0.02
Q4 FY2025+25.00%
Report Date
Nov 20, 2025
EPS Beat/Miss
—
Price Before
$0.02
Price After
$0.03
Q3 FY2025+0.00%
Report Date
Aug 19, 2025
EPS Beat/Miss
—
Price Before
$0.02
Price After
$0.02
Q1 FY2025+0.00%
Report Date
Feb 11, 2025
EPS Beat/Miss
—
Price Before
$0.04
Price After
$0.04
Q4 FY2024-14.29%
Report Date
Nov 14, 2024
EPS Beat/Miss
—
Price Before
$0.04
Price After
$0.03
Q3 FY2024+14.29%
Report Date
Aug 13, 2024
EPS Beat/Miss
—
Price Before
$0.04
Price After
$0.04
Q2 FY2024-11.11%
Report Date
Jun 25, 2024
EPS Beat/Miss
+119.0%
Price Before
$0.05
Price After
$0.04
Q1 FY2024+0.00%
Report Date
Feb 13, 2024
EPS Beat/Miss
-100.0%
Price Before
$0.03
Price After
$0.03
Avg Beat Reaction-11.11%
Avg Miss Reaction+0.00%
Beat Rate1 / 8 quarters
Largest Move+25.00% (Q4 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: APLI.TO ends December
Appili Therapeutics Inc. (APLI.TO) most recently reported earnings on February 12, 2026 for Q1 FY2026, posting EPS of $-0.01 (in line with the analyst consensus of —). The next APLI.TO earnings date is expected around September 1, 2026.
Each quarter, investors track APLI.TO earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. APLI.TO revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
APLI.TO's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
APLI.TO earnings · 4 questionsAppili Therapeutics Inc.'s next earnings report is expected around September 1, 2026. APLI.TO typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; APLI.TO historically reports after market close (AMC).
APLI.TO earnings datewhen is APLI.TO earningsAPLI.TO next earnings datewhen does APLI.TO report earningsAPLI.TO earnings calendar
▸ Source: FMP · Appili Therapeutics Inc. SEC filings · US GAAP · Appili Therapeutics Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026